Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study.

ACS omega·2026
Same author

Structural basis of NSD2 degradation via targeted recruitment of SCF-FBXO22.

Nature communications·2026
Same author

Discovery of Small-Molecule Antagonists of PHF1 and 19 Demonstrates the Ligandability of PRC2 Accessory Proteins.

ACS bio & med chem Au·2026
Same author

Binding Free Energies without Alchemy.

ArXiv·2026
Same author

Lysosomal down-regulation of the mu opioid receptor is opposed by the Retromer complex.

Science advances·2026
Same author

Enhancing Enzymatic Bioconjugation Efficiency via Computer-Based Installation of a Substrate Recruitment Domain.

Bioconjugate chemistry·2026

Related Experiment Video

Updated: Jan 18, 2026

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
10:12

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

2.7K

Development of Next Generation Cell-Permeable Peptide Inhibitors for the Oncological Target MAGE-A4.

Jiwoong Lim1,2, Lilly F Chiou3,4, Brandon Novy2,5

  • 1Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Journal of Medicinal Chemistry
|September 12, 2025
PubMed
Summary

Researchers developed JWP24, the first cell-permeable peptide inhibitor targeting Melanoma-associated antigen A4 (MAGE-A4). This breakthrough enhances DNA damage tolerance in tumor cells, advancing MAGE-A4 as an oncology target.

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.2K

Related Experiment Videos

Last Updated: Jan 18, 2026

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
10:12

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

2.7K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Melanoma-associated antigen A4 (MAGE-A4) is a cancer/testis antigen implicated in tumor cell DNA damage tolerance.
  • MAGE-A4 interacts with the E3 ubiquitin ligase RAD18, influencing cellular responses to DNA damage.

Purpose of the Study:

  • To optimize a previously identified MAGE-A4 inhibitor (MTP-1) for improved cell permeability.
  • To develop novel, cell-permeable peptide inhibitors of MAGE-A4 for potential therapeutic applications.

Main Methods:

  • Structure-guided optimization of cyclic peptides.
  • Utilized mRNA display site-saturation mutagenesis library (SSML) for structure-activity relationship (SAR) studies.
  • Employed modified cyclization strategies for scaffold optimization.

Main Results:

  • Developed JWP24, the first cell-permeable peptide inhibitor targeting MAGE-A4.
  • Demonstrated intracellular target engagement and maintained binding potency of JWP24.
  • Confirmed no cytotoxicity of JWP24 at effective concentrations.

Conclusions:

  • Established a framework for converting potent, cell-impermeable macrocyclic peptides into cell-permeable probes.
  • Progressed MAGE-A4 as a chemically tractable target in oncology.
  • JWP24 represents a significant advancement in developing targeted cancer therapies.